<DOC>
	<DOCNO>NCT02799381</DOCNO>
	<brief_summary>The primary objective study examine effect levodopa-carbidopa intestinal gel ( LCIG ) compare optimized medical treatment ( OMT ) dyskinesia participant advance Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>An Study Comparing Efficacy Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension Optimized Medical Treatment Dyskinesia Subjects With Advanced Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Dyskinesias</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Antiparkinson Agents</mesh_term>
	<criteria>Participants must diagnosis idiopathic Parkinson 's disease ( PD ) accord United Kingdom Parkinson 's Disease Society ( UKPDS ) Brain Bank Criteria Participants advance levodoparesponsive PD persistent motor fluctuation control optimized medical treatment ( OMT : maximum therapeutic effect obtain pharmacological antiparkinsonian therapy improvement expect regard additional manipulation levodopa and/or antiparkinsonian medication base Investigator 's clinical judgment ) Unified Dyskinesia Rating Scale ( UDysRs ) Total score â‰¥ 30 Visit 3 Patient ( ) treat LCIG previously Patient 's PD diagnosis unclear suspicion subject parkinsonian syndrome secondary parkinsonism ( e.g . cause drug , toxin , infectious agent , vascular disease , trauma , brain neoplasm ) , parkinsonplus syndrome ( e.g . Multiple System Atrophy , Progressive supranuclear Palsy , Diffuse Lewy Body disease ) neurodegenerative disease might mimic symptom PD Patient ( ) undergone neurosurgery treatment Parkinson 's disease . Patient ( ) contraindication levodopa ( e.g . narrow angle glaucoma , malignant melanoma ) Patient ( ) experience clinically significant sleep attack clinically significant impulsive behavior ( e.g . pathological gambling , hypersexuality ) point three month prior Screening evaluation judge Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>efficacy</keyword>
	<keyword>carbidopa</keyword>
	<keyword>levodopa</keyword>
	<keyword>levodopa-carbidopa intestinal gel</keyword>
</DOC>